title: Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation: long-term results from the Bio-CAPTURE registry.
abstract: BACKGROUND
  Drug survival is an indicator for treatment success; insight in predictors associated with drug survival is important.
  To analyse the long-term drug survival for adalimumab in patients with psoriasis treated in daily practice and (II) to identify predictors of prolonged drug survival for adalimumab split for different reasons of discontinuation.
  
  
  METHODS
  Data were extracted from a prospective psoriasis cohort and analysed using Kaplan-Meier survival curves split for reasons of discontinuation. Baseline predictors associated with longer drug survival were identified using multivariate Cox-regression analysis.
  
  
  RESULTS
  One hundred and sixteen patients were included with a total of 208 patient-years. Overall drug survival was 76% after 1 year and 52% after 4.5 years. In patients who stopped due to ineffectiveness, longer drug survival was associated with the absence of specific comorbidities (P = 0.03). In patients who stopped due to side-effects, longer drug survival was associated with male gender (P = 0.02).
  
  
  CONCLUSIONS
  Predictors of adalimumab drug survival in psoriasis differ by reason for discontinuation. Strong, specific predictors can lead to patient-tailored treatment.
authors.affiliation: Department of Dermatology, Radboud university medical center, Nijmegen, the Netherlands.
authors.forename: J M P A
authors.initials: JM
authors.lastname: van den Reek
authors.forename: M
authors.initials: M
authors.lastname: Tummers
authors.forename: J
authors.initials: J
authors.lastname: Zweegers
authors.forename: M M B
authors.initials: MM
authors.lastname: Seyger
authors.forename: P P M
authors.initials: PP
authors.lastname: van Lümig
authors.forename: R J B
authors.initials: RJ
authors.lastname: Driessen
authors.forename: P C M
authors.initials: PC
authors.lastname: van de Kerkhof
authors.forename: W
authors.initials: W
authors.lastname: Kievit
authors.forename: E M G J
authors.initials: EM
authors.lastname: de Jong
mesh_terms: D000068879:Adalimumab / Q000627:therapeutic use*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*
chemical_list: D000893:Anti-Inflammatory Agents; D000068879:Adalimumab